ABT
$ABT (Abbott Laboratories) $53.92 crossed its 1st Pivot Point Resistance #emppv #stocks
http://empirasign.com/l/6wno.htm
ABT
$ABT (Abbott Laboratories) $53.38 crossed its 1st Pivot Point Support #emppv #stocks
http://empirasign.com/l/jewa.htm
ABT
Looking for support at/near $SPX 1050 added to OAKBX FNARX FEMKX $ABT $MO - $$
ABT
$ABT (Abbott Laboratories) $54.12 crossed its 1st Pivot Point Support #emppv #stocks
http://empirasign.com/l/jkb0.htm
ABT
Abbott $ABT Labs won't lose appetite for acquisitions under Miles White following year of drug, nutrition and device buys. http://tr.im/ML7F
ABT
RT @empirasign_eq: Empirasign Most Popular Tweets for Feb 2 http://empirasign.com/l/2ti.htm $ABT $WFMI $MMC $DUK #metals #stocks #popular #e
ABT
Empirasign Most Popular Tweets for Feb 2 http://empirasign.com/l/2ti.htm $ABT $WFMI $MMC $DUK #metals #stocks #popular #emga
ABT
$ABT (Abbott Laboratories) $54.40 crossed its 3rd Pivot Point Resistance #emppv #stocks
http://empirasign.com/l/il4.htm
ABT
$ABT (Abbott Laboratories) $54.40 has crossed its 50 day moving average: $54.28 #empta #stocks
http://empirasign.com/l/jus.htm
ABT
$ABT (Abbott Laboratories) $54.18 crossed its 2nd Pivot Point Resistance #emppv #stocks
http://empirasign.com/l/w8v.htm
ABT
$ABT (Abbott Laboratories) $53.74 crossed its 1st Pivot Point Resistance #emppv #stocks
http://empirasign.com/l/36a.htm
ABT
$ABT (Abbott Laboratories) $53.11 crossed its 2nd Pivot Point Support #emppv #stocks
http://empirasign.com/l/xrl.htm
ABT
$ABT (Abbott Laboratories) $53.48 crossed its 1st Pivot Point Support #emppv #stocks
http://empirasign.com/l/inu.htm
ABT
A Greek Tragedy? http://cnbc.com/id/35126510 $AAPL $ABT $BA $BMY $CL $MMM $PG #StockPicks #StockMarket - http://tinyurl.com/yfzl6y3
ABT
A Greek Tragedy? http://cnbc.com/id/35126510 $AAPL $ABT $BA $BMY $CL $MMM $PG #StockPicks #StockMarket
Abbott Laboratories - ABT Insiders
No Insiders
We have no insiders for Abbott Laboratories right now.
Know someone who is an insider on Abbott Laboratories?
Let us know.
Abbott Laboratories - ABT information
Abbott Laboratories manufactures and sells health care products worldwide. The company?s Pharmaceutical Products segment offers adult and pediatric pharmaceuticals for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, dyslipidemia, HIV infection, hypothyroidism, advanced prostate cancer, endometriosis and central precocious puberty, anemia caused by uterine fibroids, obesity, epilepsy and bipolar disorder, migraines, and secondary hyperparathyroidism; and provides anesthesia products and anti-infectives. Its Diagnostic Products segment offers immunoassay systems; chemistry systems; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases; instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infections agents; genomic-based tests; hematology systems and reagents; and point-of-care diagnostic systems and tests for blood analysis. The company?s Nutritional Products segment provides various forms of prepared infant formula and follow-on formula, adult and other pediatric nutritional products, nutritional products used in enteral feeding in health care institutions, and bars and nutritional brands. Its Vascular Products segment offers coronary, endovascular, and vessel closure devices, such as drug-eluting coronary stent systems, coronary metallic stents, balloon dilatation products, coronary guidewires, vessel closure devices, and carotid stent systems to treat vascular disease. Abbott serves wholesalers, government agencies, health care facilities, specialty pharmacies, independent retailers, hospitals, clinics, physicians' offices, blood banks, commercial laboratories, alternate-care testing sites, plasma protein therapeutic companies, and third-party distributors. The company was founded in 1888 and is based in Abbott Park, Illinois....
www.abbott.com
73,000 Employees
Founded in 1888
ABBOTT LABORATORIES (ABT:New York)
LAST $50.61 USD
CHANGE TODAY +0.34 0.68%
VOLUME 5.0M
As of 8:04 PM 09/2/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of ABBOTT LABORATORIES (ABT)
|
OPEN
$50.21
|
PREVIOUS CLOSE
$50.27
|
|
|
DAY HIGH
$50.63
|
DAY LOW
$50.21
|
|
|
52 WEEK HIGH
01/20/10 - $56.79
|
52 WEEK LOW
07/21/10 - $44.59
|
|
|
MARKET CAP
78.1B
|
AVERAGE VOLUME 10 D
6.3M
|
|
|
EPS TTM
$3.95
|
SHARES OUTSTANDING
1.5B
|
|
|
EX-DATE
07/13/10
|
P/E TTM
12.8x
|
|
|
DIVIDEND
$1.76
|
DIVIDEND YIELD
3.32%
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Final Glance: Medical Devices companies
AP Digital - 09/02/2010 6:04 PM ET
Midday Glance: Medical Devices companies
AP Digital - 09/02/2010 1:17 PM ET
Early Glance: Medical Devices companies
AP Digital - 09/02/2010 10:32 AM ET
*Final Glance: Medical Devices companies
AP Digital - 09/01/2010 6:02 PM ET
Journal editors question sale of diet pill Meridia
AP Digital - 09/01/2010 5:57 PM ET
Key developments for ABBOTT LABORATORIES (ABT)
Abbott Laboratories Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment
09/1/2010
Abbott Laboratories announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus (HBV) in a patient's blood. It is the first and only approved test capable of automating HBV viral load testing from sample extraction to final results. The Abbott RealTime HBV assay, based on real-time PCR (polymerase chain reaction) technology, is now available for laboratories that use the Abbott m2000 automated instrument system for molecular diagnostic testing. The test offers sensitive measurement (quantitation) of HBV in human plasma or serum from individuals chronically infected with HBV. The assay is intended for use as an aid in the management of patients with chronic HBV infection undergoing anti-viral therapy. The assay can be used to measure HBV DNA levels at baseline and during treatment to aid in assessing response to treatment. Assay results must be interpreted within the context of all relevant clinical and lab findings. Use of the assay to determine the clinical stage of HBV infection has not been established. Clinical performance characteristics have been established for individuals treated with adefovir dipivoxil. The assay is not intended as a screening test for HBV or as a diagnostic test for confirming the presence of HBV infection.
Abbott Terminates its Developing, Licensing and Marketing Agreement with Skyepharma
08/23/2010
Abbott Laboratories has terminated its developing, licensing and marketing agreement with SkyePharma plc for its asthma treatment Flutiform (fluticasone propionate and formoterol fumarate) in the United States. As such, SkyePharma has recovered the rights for the product, currently under investigation as a treatment for patients of 12 years of age and older with persistent asthma. SkyePharma will continue seeking possible ways to put forward Flutiform's application in the United States. In accordance with the agreement, no payments are required for the termination.
Abbott Laboratories Presents at Wedbush Life Sciences MAC Best Ideas 2010, Aug-03-2010 02:10 PM
08/2/2010
Abbott Laboratories Presents at Wedbush Life Sciences MAC Best Ideas 2010, Aug-03-2010 02:10 PM. Venue: Le Parker Meridien, 118 West 57th Street, New York, NY 10019, United States. Speakers: Thomas C. Freyman, Chief Financial Officer and Executive Vice President of Finance.
ABT Competitors
| Company | Last | Change |
| Bayer AG | €49.05 EUR | -0.425 |
| Express Scripts Inc | $43.79 USD | -0.06 |
| Koninklijke Philips Electronics NV | €23.37 EUR | +0.10 |
| Merck & Co Inc | $35.35 USD | -0.27 |
| Sanofi-Aventis SA | €46.38 EUR | -0.245 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | ABT | Industry Range |
| Price/Earnings | 14.7x |
|
| Price/Sales | 2.3x |
|
| Price/Book | 3.9x |
|
| Price/Cash Flow | 14.6x |
|
| TEV/Sales | 1.7x |
|
|
ABT |
||
|
ABT transactions
| Type Date |
Target |
|
Private Placement
June 3, 2010 |
Voyage Medical, Inc. |
|
Merger/Acquisition
May 12, 2010 |
Angioblast Systems, Inc. |
|
Bankruptcy
May 10, 2010 |
CLENDO Lab, Inc. |
Abbott Laboratories - ABT news
Orexigen Fattens Its Coffers With Takeda Cash
2010-09-03 03:04:10
Keywords: fat,obesity,contrave,lorquess,qnexa,lorcaserin,diet pill,weightloss pills,obesity drugs,orexigen,takeda pharmaceuticals,biotech stocks,MARKETS,OREX,AMLN,ARNA,VVUS,ABT
Quote: It doesn't help that the same panel of experts will be doing two-day duty -- they'll be presiding over the advisory meeting for Abbott Laboratories' ABT) obesity drug Meridia the day before. New data has shown that the already-approved drug has major safety concerns. (Join Minyanville on September 15 for the live blog of the Meridia panel). Orexigen will be keeping a close eye on Vivus' Qnexa. Unlike Lorquess, Qnexa and Contrave are both combination pills. Contrave is a combination of two therap...Read article
UPDATE - Orexigen, Takeda in $1 bln deal for obesity drug
2010-09-03 03:04:08
Keywords: Pharmaceuticals - Generic / Specialty,Biotechnology / Pharmaceuticals,United States,Japan,Canada,Mexico,Regulations / Standards,Biotechnology / Medical Research,Biotechnology / Medical Research,Results Forecasts / Warnings,Pharmaceuticals - Diversified,Vo
Quote: The mid-September Arena panel review will follow a hearing
on Meridia, a diet drug sold by Abbott Laboratories (ABT.N)
that has been pulled from the market in Europe due to
heart-related risks. JP Morgan analyst Cory Kasimov expected a partnership for
Contrave would conclude only after the upcoming panel. "That said, we are cautious not to read into Takeda's
aggressive investment in the obesity space ... a $50 million
upfront payment does not appear to reflect a high conviction
expectation on ap...Read article
Abbott ends auction of vaccines business-company
2010-09-03 03:04:07
Keywords: Pharmaceuticals - Diversified,Biotechnology / Pharmaceuticals,United States,Healthcare,Pharmaceuticals,Pharmaceuticals / Medical Research,Mergers / Acquisitions / Takeovers,Company Events,Deals,Company News item,Economic news, EC, business/financial pages
Quote: NEW YORK, Sept 2 |Thu Sep 2, 2010 7:33pm EDT
NEW YORK, Sept 2 (Reuters) - Drugmaker Abbott Laboratories
(ABT.N) has decided against the sale of its European
flu-vaccine business after initial bids came in below its
expectations, a company spokeswoman confirmed. The news was first reported by The Wall Street Journal. The auction had drawn interest from four or five bidders,
but the offers came in at less than 500 million euros ($640
million) and proved too low for the company's liking, a person
f...Read article
Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment
2010-09-02 09:07:06
Keywords: Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment, abt
Quote: Read article
CORRECTED - Abbott's diet drug study renews calls for U.S. ban
2010-09-02 09:07:03
Keywords: Pharmaceuticals - Diversified,Biotechnology / Pharmaceuticals,United States,US Government News,Regulations / Standards,Health / Medicine,Science,Healthcare,Pharmaceuticals,Pharmaceuticals / Medical Research,General News,Politics / International Affairs /
Quote: Read article
Journal editors question sale of diet pill Meridia
2010-09-02 09:07:03
Keywords: Journal editors question sale of diet pill Meridia, abt
Quote: The difference was mostly in heart attack and stroke; there was no difference in deaths between the groups.A person taking Meridia had a 1-in-70 chance of suffering a heart attack or stroke, or a 1-in-52 chance if they had pre-existing heart problems, the editors wrote.There was no increased risk in the group with diabetes but no heart problems, the researchers found.Meridia also led to only modest weight loss: about 10 pounds over 12 months for someone weighing an average of 211 pounds.The rese...Read article
Equity Research on GlaxoSmithKline and Abbott Laboratories - The Emerging Markets Opportunities
2010-09-01 09:58:41
Keywords: Equity Research on GlaxoSmithKline and Abbott Laboratories - The Emerging Markets Opportunities, abt,gsk
Quote: JOHANNESBURG, SOUTH AFRICA--(Marketwire - 09/01/10) - www.stockcall.com/ offers investors comprehensive research on the major drug manufacturers industry and has completed analytical research on GlaxoSmithKline GSKNews) and Abbott Laboratories ABTNewswww.stockcall.com/ to have free access to these researches.https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the major drug manufacturers industry.www.stockcall.com/https://stockcall.com/d...Read article
Blacks more prone to blood clots after stents
2010-08-31 05:49:10
Keywords: Advanced medical equipment,Biotechnology / Pharmaceuticals,United States,Pharmaceuticals - Diversified,France,Western Europe,Europe,Health / Medicine,Regulations / Standards,Living / Lifestyle,Healthcare,Healthcare services,Healthcare equipment and suppli
Quote: Stents, made by companies such as Boston Scientific
(BSX.N), Abbott Laboratories (ABT.N), Medtronic Inc (MDT.N) and
Johnson & Johnson (JNJ.N), are wire-mesh coils used to prop
open arteries narrowed by fatty deposits called plaque. Many models release drugs over time that help prevent scar
tissue from building up and blocking the artery. Sanofi-Aventis' (SASY.PA) anti-clotting drug clopidogrel or
Plavix is typically prescribed after a stent is implanted to
keep patients from developing blood...Read article
Emerging Markets to Drive Health Care ETFs
2010-08-27 01:39:19
Keywords: developing nations,healthcare etf,drug sales,gdp per capita,eli lilly stock,abbott laboratories stock,,INVESTING,IXJ,IHE,VHT,LLY,ABT
Quote: For other big players in the health-care world, Abbott LaboratoriesABT) made its push into emerging markets with its acquisition of Indian drug company Piramal Healthcare, which has the largest drug sales force in India, earlier this year. As noted earlier, some ways to play the anticipated growth of health care in emerging markets includes: FREE 14 day trial to the Grail ETF & Equity InvestorLearn more.SmartStops.net.......Read article
Biotech Report: The new diet pills: fad, fact or fiction?
2010-08-26 04:51:47
Keywords: Industries|Healthcare, VVUS, Vivus Inc, OREX, Orexigen Therapeutics Inc, ARNA, Arena Pharmaceuticals Inc , ABT, Abbott Laboratories
Quote: Kenneth Snow, senior staff physician at the Joslin Diabetes Center in Boston.See CDC obesity statisticsAbout one-third of Americans are now classified as overweight, with another third considered obese, leaving only 30% of us in the "normal" or "underweight" categories.Click here to calculate your BMIHungry for more optionsCurrently, the weight-loss drug market is dominated by two drugs: phentermine, which has been on the market for decades, and Abbott Laboratories'/quotes/comstock/13*!abt/quote...Read article
Medtronic: A Mirror of Medtech Slowdown
2010-08-26 04:51:46
Keywords: medical devices,medtech,stents,medical device manufacturers,medical device companies,MARKETS,MDT,BSX,SYK,STJ,JNJ
Quote: “Although we have experienced a slowdown in the markets of our largest businesses, the investments we are making in emerging markets and emerging therapies will allow us to achieve market-leading performance over the long-term."For now, investors will have to wait and see if Hawkins can actually deliver, or if the company will lose further ground to competitors like Johnson & JohnsonJNJ) and Abbott LaboratoriesABT) which have large diversified product bases. If you're a long-term ...Read article
Study links severe drug reaction to herpes virus
2010-08-26 04:51:45
Keywords: Pharmaceuticals - Diversified,Biotechnology / Pharmaceuticals,United Kingdom,Western Europe,Europe,United States,France,Switzerland,Health / Medicine,Science,Healthcare,Pharmaceuticals,Pharmaceuticals / Medical Research,Company News item,General news stor
Quote: The main drugs that cause DRESS are anticonvulsants, often
used for epilepsy, including carbamazepine, sold as Carbatrol by
Shire (SHP.L), valproate, sold by Abbott Laboratories (ABT.N) as
Depakine and Sanofi-Aventis (SASY.PA......Read article
Chamber of Commerce Reenters Dark Ages
2010-08-23 08:38:16
Keywords: chamber of commerce,brad peck,pay gap,gender equality,equal pay,,SPECIAL FEATURES,PM,IEP,VMED,LINTA,LLL
Quote: Read article
UPDATE - SkyePharma says Abbott ends U.S. Flutiform deal
2010-08-20 09:40:27
Keywords: United Kingdom,Western Europe,Europe,Corporate Results,Results Forecasts / Warnings,Pharmaceuticals - Generic / Specialty,Biotechnology / Pharmaceuticals,Pharmaceuticals - Diversified,United States,Regulations / Standards,Company Events,Company News item,
Quote: Fri Aug 20, 2010 4:06am EDT
* Drug faces high regulatory hurdles in United States * SkyePharma not giving up on drug but needs new partner * SkyePharma shares down 5 percent LONDON, Aug 19 (Reuters) - Britain's SkyePharma (SKP.L)
said Abbott Laboratories (ABT.N) has ended its deal to
market SkyePharma's asthma drug Flutiform in the United
States, after regulators imposed what could be
insurmountable hurdles to approval. Abbott had already handed over control of the U.S
application to SkyePharma...Read article
Why Some Analysts See Bleak Future for Eli Lilly
2010-08-18 01:27:48
Keywords: eli lilly,Cymbalta,Strattera,patent expiration,drug pipeline,M&A,semagacestat,Alzheimer's disease,teva pharmaceuticals,mylan,merck,pfizer,MARKETS,LLY,TEVA,MYL,MRK,PFE
Quote: Peers like Abbott Laboratories ABT), GlaxoSmithKlineGSK), and Bristol-Myers SquibbBMY) are far more appealing as acquirers and have been snatching up smaller targets at a rapid pace trying to pad their own ailing top lines.This leaves few options for Lilly, which has been doing little beyond cutting costs to stanch its bleeding revenues (the company has plans to cut 5,500 jobs by the end of next year). The Big Pharma will need a few pipeline surprises if it's going to get back in the competition...Read article
UPDATE - Australia's CSL to focus on small acquisitions
2010-08-18 01:27:46
Keywords: Australia,Asia/Pacific,Biotechnology / Pharmaceuticals,Corporate Results,Results Forecasts / Warnings,Dividend,Biotechnology / Medical Research,Pharmaceuticals - Diversified,United States,Pharmaceuticals - Generic / Specialty,Spain,Western Europe,Europe,M
Quote: Read article
Abbott spent $600,000 on lobbying in 1Q
2010-08-16 08:22:51
Keywords: Abbott spent $600,000 on lobbying in 1Q, abt
Quote: WASHINGTON (AP) -- Drug and medical device maker Abbott Laboratories spent over $600,000 in the second quarter to lobby the federal government on policies affecting its products.The North Chicago-based company spent $620,000 in the most recent period, down from $1.5 million in the first quarter of the year when Congress was finalizing the administration's health care overhaul.Abbott lobbied on the implementation of provisions of the bill that give the Food and Drug Administration authority to ap...Read article
Built-In Medicine Cabinet
2010-08-13 01:55:48
Keywords: diabetes, microfabrication, osteoporosis, drug delivery, eli lilly, medtronic, cancer
Quote: Implanted blood glucose monitors made by MedtronicMDTnewspeople), Dexcom and Abbott LaboratoriesABTnewspeople) must be inserted into the skin like a syringe and lose their ability to measure sugar within a week as bodily fluids foul the chemicals within. MicroChips has created an implantable device that contains arrays of tiny sensors, each sealed under the platinum foil. When one array fails, a new one opens up, allowing the device to function for a full year. This would be a boon for physician...Read article
UPDATE - Emergent to buy Trubion Pharma for up to $135.5 mln
2010-08-13 01:55:47
Keywords: Healthcare facilities,Commercial services and supplies (industry group),Industrial machinery,Machinery,United States of America,Healthcare,Mergers and Acquisitions (including Changes of Ownership),Contract between 2 or more corporate entities,Healthcare p
Quote: Seattle-based Trubion develops treatments for autoimmune
diseases such as rheumatoid arthritis and lupus in partnership
with Pfizer Inc (PFE.N) and for cancers such as leukemia and
lymphoma with Abbott Laboratories (ABT.N).Emergent will also make milestone payments of up to $38.7
million to buy Trubion. Emergent also backed its 2010 outlook of about $275-$300
million in total revenue and $40-$50 million in net income. The deal is expected to close in the fourth quarter of
2010, Emergent said in ...Read article